Acer Therapeutics Inc. (ACER)
Price:
0.66 USD
( - -0.14 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Regeneron Pharmaceuticals, Inc.
VALUE SCORE:
6
2nd position
Harmony Biosciences Holdings, Inc.
VALUE SCORE:
12
The best
Agios Pharmaceuticals, Inc.
VALUE SCORE:
12
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
No data to display
No data to display
No data to display
No data to display
DESCRIPTION
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was incorporated in 1991 and is headquartered in Newton, Massachusetts.
NEWS
Russian LNG on the rise in EU – report
rt.com
2024-10-22 07:19:10Russian LNG accounts for one-fifth of all EU imports, the economic bloc’s energy watchdog (ACER) has reported Read Full Article at RT.com...
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Acer Therapeutics Shareholders Vote "FOR" the Proposed Merger and Related Proposals
globenewswire.com
2023-11-02 08:30:00NEWTON, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER ), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today announced that Institutional Shareholder Services Inc. (ISS) and Glass, Lewis & Co. LLC (Glass Lewis) recommended that Acer shareholders vote "FOR" the proposed merger with Zevra Therapeutics, Inc. and the related proposals in the Company's proxy statement and prospectus for the special meeting of its shareholders to be held on November 8, 2023 at 11:00 a.m.
PC demand is back, says Acer CEO who sees robust growth in the 'foreseeable future'
cnbc.com
2023-10-20 00:50:43Acer CEO Jason Chen said that PC demand hit a bottom in May, but demand has come back since then.
ACER THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acer Therapeutics Inc. - ACER
businesswire.com
2023-10-10 10:28:00NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Acer Therapeutics Inc. (NasdaqCM: ACER) to Zevra Therapeutics, Inc. (NasdaqGS: ZVRA). Under the terms of the proposed transaction, shareholders of Acer will receive 0.121 shares of Zevra for each share of Acer that they own. Additionally, Acer stockholders would receive non-transferable Contingent Value Rights.
ACER THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acer Therapeutics Inc. - ACER
businesswire.com
2023-09-05 18:49:00NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Acer Therapeutics Inc. (NasdaqCM: ACER) to Zevra Therapeutics, Inc. (NasdaqGS: ZVRA). Under the terms of the proposed transaction, shareholders of Acer will receive 0.121 shares of Zevra for each share of Acer that they own. Additionally, Acer stockholders would receive non-transferable Contingent Value Rights.
Acer (ACER) to Get Acquired by Zevra for $91M, Stock Up
zacks.com
2023-09-01 09:02:33Acer (ACER) surges as Zevra Therapeutics offers to acquire it for approximately $91 million.
Shareholder Alert: Ademi LLP investigates whether Acer Therapeutics Inc. has obtained a Fair Price in its transaction with Zevra
prnewswire.com
2023-08-31 11:30:00MILWAUKEE , Aug. 31, 2023 /PRNewswire/ -- Ademi LLP is investigating Acer (Nasdaq: ACER) for possible breaches of fiduciary duty and other violations of law in its transaction with Zevra. Click here to learn how to join the action https://www.ademilaw.com/case/acer-therapeutics-inc or call Guri Ademi toll-free at 866-264-3995.
ACER Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Acer Therapeutics Inc. Is Fair to Shareholders
businesswire.com
2023-08-31 09:29:00NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Acer Therapeutics Inc. (NASDAQ: ACER) to Zevra Therapeutics, Inc. for 0.121 of a share of Zevra's common stock for each share of Acer's common stock is fair to Acer shareholders. Additionally, Acer stockholders would receive non-transferable Contingent Value Rights entitling them to receive up to $34 million in cash upon the achievement of certain commercial milestones for OLPRUVA, and.
Why Is Acer Therapeutics (ACER) Stock Up 85% Today?
investorplace.com
2023-08-31 08:49:58Acer Therapeutics (NASDAQ: ACER ) stock is taking off on Thursday after the pharmaceutical company announced an acquisition deal with Zevra Therapeutics (NASDAQ: ZVRA ). According to a press release from the company, Zevra Therapeutics will be acquiring it with $15 million worth of ZVRA stock.
Acer Therapeutics Reacquires Worldwide Development, Commercialization and Economic Rights to OLPRUVA™ from Relief Therapeutics, Excluding the Geographical Europe
globenewswire.com
2023-08-30 16:05:00NEWTON, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER ), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today announced it has entered into definitive agreements to reacquire worldwide development, commercialization and economic rights to OLPRUVA™ (sodium phenylbutyrate) from Relief Therapeutics, excluding the European Union, Liechtenstein, San Marino, Vatican City, Norway, Iceland, Principality of Monaco, Andorra, Gibraltar, Switzerland, United Kingdom, Albania, Bosnia, Kosovo, Montenegro, Serbia and North Macedonia (Geographical Europe). OLPRUVA™ is approved in the U.S. for the treatment of certain urea cycle disorders (UCDs).
Acer Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
globenewswire.com
2023-08-14 16:05:00OLPRUVA™ (sodium phenylbutyrate) kits now available in all dosage strengths and ready to ship to patients OLPRUVA™ (sodium phenylbutyrate) kits now available in all dosage strengths and ready to ship to patients
ACER's Stock Down on Failure of Phase II Study, Cash Updates
zacks.com
2023-03-20 13:46:12ACER announces the failure of its phase IIa study of ACER-801 to treat vasomotor symptoms associated with menopause, along with its extinguishing cash runway. Stock down.
7 Penny Stocks With Strong Insider Buying Signals
investorplace.com
2023-03-05 12:10:56When it comes to penny stocks, a diligent look at fundamentals and insider activity should be key to your research. After all, penny stocks with strong insider buying can potentially be strong opportunities.
5 Stocks to Buy as the Drug Industry Bets Big on Innovation
zacks.com
2023-01-18 10:33:52Innovation is expected to continue driving growth in the Medical-Drugs industry in 2023. DYN, SLN, TCRT, ASRT and ACER may prove to be good additions to one's portfolio.
Are Medical Stocks Lagging Acer Therapeutics (ACER) This Year?
zacks.com
2023-01-16 11:17:40Here is how Acer Therapeutics Inc. (ACER) and Syndax Pharmaceuticals (SNDX) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Acer Therapeutics (ACER) This Year?
zacks.com
2022-12-29 11:17:41Here is how Acer Therapeutics Inc. (ACER) and Cardinal Health (CAH) have performed compared to their sector so far this year.
No data to display
Russian LNG on the rise in EU – report
rt.com
2024-10-22 07:19:10Russian LNG accounts for one-fifth of all EU imports, the economic bloc’s energy watchdog (ACER) has reported Read Full Article at RT.com...
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Acer Therapeutics Shareholders Vote "FOR" the Proposed Merger and Related Proposals
globenewswire.com
2023-11-02 08:30:00NEWTON, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER ), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today announced that Institutional Shareholder Services Inc. (ISS) and Glass, Lewis & Co. LLC (Glass Lewis) recommended that Acer shareholders vote "FOR" the proposed merger with Zevra Therapeutics, Inc. and the related proposals in the Company's proxy statement and prospectus for the special meeting of its shareholders to be held on November 8, 2023 at 11:00 a.m.
PC demand is back, says Acer CEO who sees robust growth in the 'foreseeable future'
cnbc.com
2023-10-20 00:50:43Acer CEO Jason Chen said that PC demand hit a bottom in May, but demand has come back since then.
ACER THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acer Therapeutics Inc. - ACER
businesswire.com
2023-10-10 10:28:00NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Acer Therapeutics Inc. (NasdaqCM: ACER) to Zevra Therapeutics, Inc. (NasdaqGS: ZVRA). Under the terms of the proposed transaction, shareholders of Acer will receive 0.121 shares of Zevra for each share of Acer that they own. Additionally, Acer stockholders would receive non-transferable Contingent Value Rights.
ACER THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acer Therapeutics Inc. - ACER
businesswire.com
2023-09-05 18:49:00NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Acer Therapeutics Inc. (NasdaqCM: ACER) to Zevra Therapeutics, Inc. (NasdaqGS: ZVRA). Under the terms of the proposed transaction, shareholders of Acer will receive 0.121 shares of Zevra for each share of Acer that they own. Additionally, Acer stockholders would receive non-transferable Contingent Value Rights.
Acer (ACER) to Get Acquired by Zevra for $91M, Stock Up
zacks.com
2023-09-01 09:02:33Acer (ACER) surges as Zevra Therapeutics offers to acquire it for approximately $91 million.
Shareholder Alert: Ademi LLP investigates whether Acer Therapeutics Inc. has obtained a Fair Price in its transaction with Zevra
prnewswire.com
2023-08-31 11:30:00MILWAUKEE , Aug. 31, 2023 /PRNewswire/ -- Ademi LLP is investigating Acer (Nasdaq: ACER) for possible breaches of fiduciary duty and other violations of law in its transaction with Zevra. Click here to learn how to join the action https://www.ademilaw.com/case/acer-therapeutics-inc or call Guri Ademi toll-free at 866-264-3995.
ACER Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Acer Therapeutics Inc. Is Fair to Shareholders
businesswire.com
2023-08-31 09:29:00NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Acer Therapeutics Inc. (NASDAQ: ACER) to Zevra Therapeutics, Inc. for 0.121 of a share of Zevra's common stock for each share of Acer's common stock is fair to Acer shareholders. Additionally, Acer stockholders would receive non-transferable Contingent Value Rights entitling them to receive up to $34 million in cash upon the achievement of certain commercial milestones for OLPRUVA, and.
Why Is Acer Therapeutics (ACER) Stock Up 85% Today?
investorplace.com
2023-08-31 08:49:58Acer Therapeutics (NASDAQ: ACER ) stock is taking off on Thursday after the pharmaceutical company announced an acquisition deal with Zevra Therapeutics (NASDAQ: ZVRA ). According to a press release from the company, Zevra Therapeutics will be acquiring it with $15 million worth of ZVRA stock.
Acer Therapeutics Reacquires Worldwide Development, Commercialization and Economic Rights to OLPRUVA™ from Relief Therapeutics, Excluding the Geographical Europe
globenewswire.com
2023-08-30 16:05:00NEWTON, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER ), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today announced it has entered into definitive agreements to reacquire worldwide development, commercialization and economic rights to OLPRUVA™ (sodium phenylbutyrate) from Relief Therapeutics, excluding the European Union, Liechtenstein, San Marino, Vatican City, Norway, Iceland, Principality of Monaco, Andorra, Gibraltar, Switzerland, United Kingdom, Albania, Bosnia, Kosovo, Montenegro, Serbia and North Macedonia (Geographical Europe). OLPRUVA™ is approved in the U.S. for the treatment of certain urea cycle disorders (UCDs).
Acer Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
globenewswire.com
2023-08-14 16:05:00OLPRUVA™ (sodium phenylbutyrate) kits now available in all dosage strengths and ready to ship to patients OLPRUVA™ (sodium phenylbutyrate) kits now available in all dosage strengths and ready to ship to patients
ACER's Stock Down on Failure of Phase II Study, Cash Updates
zacks.com
2023-03-20 13:46:12ACER announces the failure of its phase IIa study of ACER-801 to treat vasomotor symptoms associated with menopause, along with its extinguishing cash runway. Stock down.
7 Penny Stocks With Strong Insider Buying Signals
investorplace.com
2023-03-05 12:10:56When it comes to penny stocks, a diligent look at fundamentals and insider activity should be key to your research. After all, penny stocks with strong insider buying can potentially be strong opportunities.
5 Stocks to Buy as the Drug Industry Bets Big on Innovation
zacks.com
2023-01-18 10:33:52Innovation is expected to continue driving growth in the Medical-Drugs industry in 2023. DYN, SLN, TCRT, ASRT and ACER may prove to be good additions to one's portfolio.
Are Medical Stocks Lagging Acer Therapeutics (ACER) This Year?
zacks.com
2023-01-16 11:17:40Here is how Acer Therapeutics Inc. (ACER) and Syndax Pharmaceuticals (SNDX) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Acer Therapeutics (ACER) This Year?
zacks.com
2022-12-29 11:17:41Here is how Acer Therapeutics Inc. (ACER) and Cardinal Health (CAH) have performed compared to their sector so far this year.